Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Clinical trial NCT00109161 · COMPLETED

Trial details

NCT number: NCT00109161
Sponsor: PDL BioPharma, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Sclerosis

Start date: 2005-04-01
Enrollment: 270

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.